The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | GvHD in MM patients treated w/ dara post-alloHCT
Joshua Richter, Mount Sinai Medical Center, New York, NY, discusses a multicenter retrospective study which evaluated the incidence of graft-versus-host disease (GvHD) in 34 patients with relapsed multiple myeloma treated with daratumumab after allogeneic hematopoietic cell transplantation (allo-HCT). Dr Richter and his colleagues concluded that the incidence of GvHD after daratumumab was low and did not result in increased exacerbation of GvHD in patients with a history of GvHD. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology.
